EVENTS

- MAR 07 2018
Oncoceutics to present ONC212 and ONC201 at Drug Discovery Chemistry conference in San Diego – April 3+5, 2018
Oral talk 1 in section ‘GPCR-Targeted Drug Design’ Varun Prabhu: Anti-Leukemic Activity of Imipridone ONC212 via Selective Targeting of Orphan GPCR GPR132/G2A Tuesday, April 3, 2:20 pm | Hilton Bayfront | San Diego, California Oral talk 2 in section ‘Small Molecules for Cancer Immunotherapy’ Josh Allen: The Imipridone ONC201, a Selective DRD2 Antagonist, Exerts Immunostimulatory Activity

Read >
- FEB 13 2018
Josh Allen of Oncoceutics to present ONC201 at the Keystone Symposia on Molecular and Cellular Biology – Feb. 20, 2018
ONC201 to be discussed at the Keystone Symposia on Molecular and Cellular Biology on February 20, 2018 Josh Allen of Oncoceutics will be giving a Short Talk under the title of “Differentiated Receptor Pharmacology of Imipridone ONC201: The First DRD2 Antagonist in Clinical Development for Oncology”. The Short Talk is part of the Keystone Symposia

Read >

- JAN 11 2018
Lunch for Hungry Minds with Dr. Benjamin Free – Jan. 18, 2018
Dr. Benjamin Free, a collaborator with Oncoceutics on the effects of ONC201 and ONC206 on the dopamine receptor, will be presenting his research at the University City Science Center as part of the Science Center’s Lunch for Hungry Minds program. While blockade of the D2 dopamine receptor (D2R) is known to be required and primarily

Read >
- OCT 26 2017
ONC201 Biomarkers and Pharmacology at ENA Conference October 27-29th in Philadelphia
Three abstracts involving Oncoceutics’ lead clinical compound, ONC201, will be presented at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics in Philadelphia on October 28th and 29th, 2017. ONC201 is the first Dopamine Receptor 2 (DRD2) antagonist for clinic oncology and the first imipridone to enter the clinic, with 8 active clinical trials

Read >

Oncoceutics to present ONC212 and ONC201 at Drug Discovery Chemistry conference in San Diego – April 3+5, 2018